Submitted to: Symposium on Avian Pneumovirus
Publication Type: Proceedings
Publication Acceptance Date: 3/1/2004
Publication Date: 6/23/2004
Citation: Kapczynski, D.R. 2004. Virosome vaccination against avian metapneumovirus decreases clinical signs of disease and viral load following challenge. In: Proceedings of the IV International Symposium on Avian Corona-and Pneumovirus Infections, June 20-23, 2004, Giessen, Germany. p.372-381. Interpretive Summary: Not required.
Technical Abstract: An avian metapneumovirus (aMPV) virosome vaccine was prepared and tested for protection of turkeys by aMPV challenge. The virosome vaccine was produced from aMPV subtype C (Minnesota 1a strain) using a detergent-based extraction procedure. Biochemical analysis confirmed that the aMPV virosomes contained both the fusion and attachment envelope glycoproteins. Specific-pathogen-free (SPF) turkeys were immunized intranasally (I.N.) with 2 doses of the aMPV virosome vaccine. Virosome vaccination decreased clinical signs of disease following virulent challenge, and decreased virus titer in the respiratory tract. Vaccination increased antibody levels against aMPV as well as percentage of peripheral blood CD4+ lymphocytes following challenge. These results demonstrate that immunization of turkeys with aMPV virosomes can be an effective strategy for control of disease.